Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
About Chromadex Corp
Chromadex Corp (CDXC) is a globally recognized integrated nutraceutical and bioscience company committed to improving the quality of life through advanced research on healthy aging. The company is deeply invested in understanding the mechanisms by which cellular processes, particularly those involving nicotinamide adenine dinucleotide (NAD+), impact the aging process. With a core focus on innovative science, Chromadex has developed a multifaceted business model that spans from research breakthroughs to commercially available consumer products, ensuring that its scientific discoveries translate into meaningful daily benefits.
Business Model and Core Segments
Chromadex’s operational framework is built on three primary segments that work in unison to deliver high-quality, science-based nutraceutical innovations:
- Consumer Products: This segment is primarily responsible for marketing and distributing products directly to the consumer market. Its portfolio features formulations designed to support healthy aging by leveraging proprietary, scientifically validated ingredients. The company’s flagship product, built around the NAD+ precursor nicotinamide riboside (NR), exemplifies its commitment to translating rigorous research into everyday solutions.
- Ingredients Segment: Focused on the development and licensing of novel ingredients, this segment utilizes high-caliber scientific research to create bioactive compounds. These innovations are targeted for use in various applications, ranging from dietary supplements to functional foods, ensuring that the expertise of Chromadex is shared widely across the industry.
- Analytical Reference Standards and Services: This area underpins the rigorous quality control and analytical validation processes that are crucial to research and product development. By offering specialized standards and services, Chromadex supports both internal development and external quality assurance needs in a scientifically robust manner.
Research and Innovation
At the heart of Chromadex’s operations is a steadfast commitment to research and development. The company partners with leading universities and research institutions worldwide to explore the potential of critical biochemical pathways related to aging. This collaborative approach not only strengthens its research capabilities but also ensures that the ingredients developed are based on solid scientific evidence. The integration of cutting-edge bioscience and precise analytical methodologies solidifies its position as a trusted name in the nutraceutical industry.
Market Position and Competitive Differentiation
Chromadex distinguishes itself by focusing on the intersection of scientific innovation and consumer wellness. Its emphasis on NAD+ research, an area that has increasingly become synonymous with the study of aging and cellular health, sets it apart in a competitive landscape that includes various bioscience and nutraceutical companies. The company’s multidimensional approach, which bridges direct consumer engagement with deep scientific inquiry, provides a unique value proposition that caters both to health-conscious individuals and to industry partners seeking high-quality, science-backed ingredients.
Commitment to Transparency and Quality
Transparency in research and product development is a core tenet of Chromadex’s philosophy. Every stage of its process—from initial scientific exploration to the final formulation—undergoes rigorous analytical review and quality control. This disciplined approach reassures consumers and industry collaborators alike, fostering trust and establishing Chromadex as a reliable source of scientifically supported nutraceutical innovations.
Integrating Science and Consumer Wellness
The company’s approach is marked by a detailed understanding of biochemical processes and a commitment to translating this expertise into practical health solutions. With its diversified business segments, Chromadex not only addresses the needs of a broad consumer base but also solidifies its reputation among researchers and industry experts. Its dedicated exploration of key ingredients such as nicotinamide riboside, alongside other innovative compounds, continues to influence the realm of healthy aging and functional nutrition.
ChromaDex Corp. (NASDAQ: CDXC) will participate in a virtual presentation at the Benzinga Small Cap Conference on May 13, 2021, at 11:30am ET. CEO Rob Fried will present on a panel discussing longevity science at 1:20pm ET. This conference aims to connect small-cap companies with investors. ChromaDex's presentation will be available for replay on their investor relations website. The company is known for its research in healthy aging and its flagship product, Niagen®, which supports NAD+ levels that decline with age.
ChromaDex Corp. (NASDAQ:CDXC) will announce its first-quarter financial results for 2021 on May 6, 2021, with a conference call scheduled at 4:30 p.m. ET. The results will be released after market hours on the same day. Investors can access the call via a toll-free number or through the webcast link. ChromaDex is focused on healthy aging research and is known for its NAD+ precursor, nicotinamide riboside (NR), used in its flagship product, Tru Niagen®. The company emphasizes its commitment to innovation and growth.
ChromaDex Corp. (NASDAQ:CDXC) has appointed Fadi Karam as the new Chief Marketing Officer. Karam brings extensive experience in driving consumer businesses and direct-to-consumer operations. He previously led a brand portfolio for Nestlé Waters North America, managing over $3 billion in revenues, and was pivotal in global brand strategies. ChromaDex's CEO, Rob Fried, expressed confidence in Karam's ability to contribute to the growth of the company's flagship product, Tru Niagen®. Karam is enthusiastic about enhancing the brand's reach and impact.
ChromaDex Corp. (NASDAQ: CDXC) has initiated a research partnership with the Citrin Foundation of Singapore to investigate the effects of Niagen® nicotinamide riboside (NR) on citrin deficiency, a rare genetic disorder. Funded studies will focus on how increased NAD+ levels could impact mitochondrial function, inflammation, and liver conditions in affected patients. Lead research will be conducted at Duke-NUS Medical School, aiming to deepen understanding of both citrin deficiency and NAD+ roles in metabolic health.
ChromaDex Corp. (NASDAQ:CDXC) announced that CEO Rob Fried and CFO Kevin Farr will present at the Lytham Partners Spring 2021 Investor Conference.
The presentation is scheduled for March 31, 2021, at 10:15 a.m. ET. Investors can watch the live webcast via the company's website or directly through the provided link.
Additionally, management will engage in virtual one-on-one meetings during the event from March 30 to April 1, 2021, with arrangements managed through Lytham Partners.
ChromaDex Corp. (NASDAQ:CDXC) announced that its CEO Rob Fried and CFO Kevin Farr will present at the Zooming with LD investor conference on March 25, 2021, at 12:30 p.m. ET. The presentation will be streamed live on the company's investor relations website. Additionally, ChromaDex management will engage in one-on-one virtual meetings with institutional investors throughout the day. Interested parties can find more information and register for the event through the provided links.
ChromaDex Corp. (NASDAQ:CDXC) announced its fourth quarter and full-year 2020 financial results, reporting total net sales of $15.4 million for Q4, an 18% increase from the previous year. Tru Niagen® sales reached $12.3 million, up 21%. The company improved its gross margin to 61.0% and reduced its net loss to ($6.1 million), resulting in a loss per share of ($0.10). Full-year net sales were $59.3 million, a 28% increase, with a net loss of ($19.9 million). The company expects continued revenue growth and margin improvement in 2021.
ChromaDex Corp. (NASDAQ:CDXC) announced that its premier NAD+ booster, Tru Niagen®, will be available in 3,000 Walmart stores across the U.S. starting June 2021. The product will come in two packaging options with different serving sizes and price points, also available for online purchase with same-day delivery. ChromaDex's CEO, Rob Fried, emphasized the importance of Tru Niagen® in supporting healthy aging by increasing NAD+ levels, which decline with age and stressors. Niagen® has been validated in nine human trials and accepted by leading regulatory agencies.
ChromaDex Corp. (NASDAQ: CDXC) will present at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 3:50 PM ET. A webcast will be available on their investor relations page on www.chromadex.com. The company will also hold virtual meetings on March 16 and 17. ChromaDex focuses on healthy aging, specializing in nicotinamide adenine dinucleotide (NAD+) research and its precursor, nicotinamide riboside (NR), marketed as Niagen®. Their product Tru Niagen® is available through various retailers and online.
ChromaDex Corp. (NASDAQ:CDXC) has appointed Dr. David L. Katz to its Scientific Advisory Board. Dr. Katz is a prominent figure in nutrition and chronic disease prevention, previously serving as CEO of Diet ID and founding director of Yale’s Yale-Griffin Prevention Research Center. His expertise includes innovative research methods in preventive medicine, notably 'evidence mapping'. CEO Rob Fried expressed confidence that Dr. Katz's extensive background will enhance ChromaDex's mission to explore the health benefits of NAD+ and its precursors like nicotinamide riboside (NR).
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
What is Chromadex Corp's primary focus?
How does Chromadex generate its revenue?
What makes Chromadex's research unique?
What is the significance of nicotinamide riboside (NR) for Chromadex?
In which segments does Chromadex operate?
How does Chromadex ensure the quality and safety of its products?
How is Chromadex positioned within the competitive landscape?
What are the key benefits of Chromadex's integrated business model?
